Abstract
Leishmaniasis is important as a cause of hemophagocytic lymphohistiocytosis (HLH) and must be considered and excluded in patients with HLH because it can cause severe or even fatal complications. When HLH is present, there is a deficient downregulation of the immune response, leading to an uncontrolled inflammation. We report a case of visceral leishmaniasis-HLH where the therapy with tocilizumab, targeting interleukin 6, help to regulate the immune response for the infection of Leishmania.
MeSH terms
-
Adult
-
Antibodies, Monoclonal, Humanized / administration & dosage*
-
Antibodies, Monoclonal, Humanized / pharmacology
-
Antibodies, Monoclonal, Humanized / therapeutic use
-
Female
-
Humans
-
Leishmaniasis, Visceral / complications*
-
Leishmaniasis, Visceral / drug therapy
-
Leishmaniasis, Visceral / immunology
-
Lymphohistiocytosis, Hemophagocytic / drug therapy*
-
Lymphohistiocytosis, Hemophagocytic / etiology
-
Lymphohistiocytosis, Hemophagocytic / immunology
-
Receptors, Interleukin-6 / antagonists & inhibitors
-
Receptors, Interleukin-6 / immunology
Substances
-
Antibodies, Monoclonal, Humanized
-
Receptors, Interleukin-6
-
tocilizumab